ArticleStem cell research & therapy2025
Organoid-derived photoreceptor precursors enriched by CD9⁻CD81
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Photoreceptor replacement: a disease-agnostic approach for the treatment of advanced retinal degeneration.Eye (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundRetinal degenerative diseases (RDD) cause irreversible vision loss due to photoreceptor (PR) loss. Stem cell-derived PR precursors hold promise for retinal repair, but genetic labeling limits clinical translation. Surface marker-based sorting offers a safer alternative.
methodsWe analyzed single-cell RNA sequencing (scRNA-seq) datasets of human retinal organoids to identify PR-specific surface markers and validated them by immunofluorescence and flow cytometry. Cells with a CD9⁻CD81
resultsAmong the identified markers (STX3, PARD6B, PROM1, CD9⁻CD81
conclusionsWe established a clinically translatable, non-genetic strategy for enriching human PR precursors using the CD9
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.